FDA approved Takeda & Protagonist's Mimrylo (rusfertide) for polycythemia vera, a rare blood disease.
The FDA approved rusfertide, a new drug from Takeda and Protagonist Therapeutics to treat a rare blood disease.
Rusfertide, which will be branded as Mimrylo …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
FDA approves Roivant therapy for rare autoimmune disease
Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease
FDA green lights Priovant drug for rare skin disease
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment - Johnson & Johnson (NYSE:JNJ)
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
